Valvular & structural heart diseaseMeta-analysis

Meta-Analysis of Dedicated vs Off-Label Transcatheter Devices for Native Aortic Regurgitation

JACC Cardiovasc IntervPublished

  • Systematic review and meta-analysis
  • random-effects model

Authors' conclusion

Dedicated TAVR devices for native AR show superior device success and reduced mortality, residual AR, and reintervention rates compared with off-label devices.

Study context

Population
High surgical risk patients with pure severe native aortic regurgitation (AR) undergoing transcatheter aortic valve replacement (TAVR)
Participants
2,162 patients · 34 studies
Comparison
Dedicated vs off-label TAVR devices
Outcome
All-cause mortality
Follow-up
30 days

Pooled result

As reported in the abstract

P < 0.01

Further pooled results

Device success

P < 0.01

Residual AR ≥ moderate · 30 days

P = 0.03

Reintervention · 30 days

P < 0.01

All-cause mortality · 1 year

P < 0.01

Safety

Valve embolization/migration · 30 days

P < 0.01

Pacemaker implantation · 30 days

P < 0.01

Original publication

Meta-Analysis of Dedicated vs Off-Label Transcatheter Devices for Native Aortic Regurgitation. JACC Cardiovasc Interv. Published 20 November 2024. doi:10.1016/j.jcin.2024.08.042

Summarised from the published abstract; every number is checked against it